Mini organs-on-chips allow us to study how diseases develop and how drugs work. Although the technology is not new, it is becoming increasingly advanced. PhD candidate Bart Kramer hopes it will eliminate animal testing in the future.

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

Immediately connect with the needs of industry with your master’s degree. The new course Practical Aspects of Quality Management in Pharma and Biotech provides just that. The LACDR and LUMC set up the course together with the Biotech Training Facility, located at the Leiden Bio Science Park. The first…

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

Nerve pain is one of the most common side effects of chemotherapy. It is therefore one of the biggest reasons for cancer patients to stop treatment early. Darcy Reynolds worked on new drug candidates against this pain during her bachelor's thesis. She developed a new series of molecules that increase…

The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.

Aukje Beers combined theory and practice, as well as chemistry, biology, and computer models. In this way, she discovered two protein inhibitors during her master’s project that could contribute to the development of a new cancer drug. For her research, Beers received the Unilever Research Prize on…

LACDR, the Leiden Institute for Drug Research, developed better tolerated excipients to prevent adverse effects related to the surface of nanosized drugs such as vaccines. LADCR professor of Biopharmacy Matthias Barz and Polypeptide Therapeutic Solutions (PTS) are collaborating to develop processes…

One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.

Sometimes an idea seems so logical and elegant at first glance, that you later wonder why no one thought of it before. Two researchers from LACDR have teamed up to develop a completely synthetic alternative to antibodies—one that mimics their size, shape and function, but which is cheaper, more stable,…

A Dutch consortium has received €6.7 million to accelerate the development of nanomedicines together with patients. Researchers from Leiden University play a key role in the project.

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.

Leiden researchers, led by Sebastian Pomplun developed a new method to screen hundreds of thousands of molecules for drug discovery, using mass spectrometry instead of DNA tags. ‘We wanted to make drug discovery faster and more accessible.’

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

Bacteria carry countless hidden treasures in their DNA: fragments that could hold the key to new medicines. But how do you pick out the most promising ones from millions of options? ‘Look at the switches that turn genes on and off,’ says molecular biologist Gilles van Wezel.

Leiden researcher Anne-Grete Märtson brought together a large number of studies to better understand antibiotic dosing in patients with obesity. The publication in a renowned medical journal has already garnered much positive reactions, Märtson says. ‘It’s high time researchers started sharing more…

Two consortia led by Leiden researchers have been awarded over one million euros by the Dutch Research Council and the Ministry of Health, Welfare and Sport to find solutions to antimicrobial resistance.

Scientific Director of the Leiden Academic Centre for Drug Research (LACDR) Hubertus Irth: ‘We test substances and look for new concepts for treating disease.’